DK151273B - PROCEDURE FOR THE PREPARATION OF THE CHOLESTEROL BIOSYNTHESE INHIBITOR MB-530A. - Google Patents
PROCEDURE FOR THE PREPARATION OF THE CHOLESTEROL BIOSYNTHESE INHIBITOR MB-530A. Download PDFInfo
- Publication number
- DK151273B DK151273B DK145481AA DK145481A DK151273B DK 151273 B DK151273 B DK 151273B DK 145481A A DK145481A A DK 145481AA DK 145481 A DK145481 A DK 145481A DK 151273 B DK151273 B DK 151273B
- Authority
- DK
- Denmark
- Prior art keywords
- compound
- cholesterol
- culture medium
- preparation
- microorganism
- Prior art date
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title claims description 12
- 238000000034 method Methods 0.000 title claims description 8
- 235000012000 cholesterol Nutrition 0.000 title claims description 6
- 238000002360 preparation method Methods 0.000 title description 6
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 19
- 239000001963 growth medium Substances 0.000 claims description 13
- 244000005700 microbiome Species 0.000 claims description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 241000228347 Monascus <ascomycete fungus> Species 0.000 claims description 3
- 241000031003 Monascus ruber Species 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000003208 petroleum Substances 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 2
- 238000000862 absorption spectrum Methods 0.000 claims 2
- 238000004458 analytical method Methods 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 238000000921 elemental analysis Methods 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 238000002844 melting Methods 0.000 claims 1
- 230000008018 melting Effects 0.000 claims 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000001888 Peptone Substances 0.000 description 3
- 108010080698 Peptones Proteins 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 235000019319 peptone Nutrition 0.000 description 3
- 241000894007 species Species 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 238000005273 aeration Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- IIEWJVIFRVWJOD-UHFFFAOYSA-N ethylcyclohexane Chemical compound CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- 241000364057 Peoria Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- WWSNTLOVYSRDEL-DZSDEGEFSA-N compactin diol lactone Chemical compound C([C@@H]1[C@H]2[C@@H](O)CCC=C2C=C[C@@H]1C)C[C@@H]1C[C@@H](O)CC(=O)O1 WWSNTLOVYSRDEL-DZSDEGEFSA-N 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- WWSNTLOVYSRDEL-UHFFFAOYSA-N desmethylmonacolin J Natural products CC1C=CC2=CCCC(O)C2C1CCC1CC(O)CC(=O)O1 WWSNTLOVYSRDEL-UHFFFAOYSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- -1 methylglutaryl coenzyme A Chemical compound 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/02—Oxygen as only ring hetero atoms
- C12P17/06—Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/30—Oxygen atoms, e.g. delta-lactones
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
i 151273in 151273
Den foreliggende opfindelse angår en fremgangsmåde til fremstilling af forbindelsen betegnet MB-530A med inhiberende virkning overfor biosyntesen af cholesterol. MB-530A har formlen (V): 5 0 (V) 10 L i ch3^," ' Y ">xThe present invention relates to a process for the preparation of the compound termed MB-530A with inhibitory effect on the biosynthesis of cholesterol. MB-530A has the formula (V): 50 (V) 10 L in ch 3
O ^ JO ^ J
15 Hyperlipidæmi, især hypercholesterolæmi, vides at være en af hovedårsagerne til cardiopati, såsom hjerteinfarkt eller arteriesclerose. Som resultat heraf har en betydelig forskning været udført med henblik på at finde frem til forbindelser, der er i stand til at formindske lipidmængden, og især chole- 2Q sterolmængden i blodet. En gruppe forbindelser af denne type er omhandlet i USA-patentskrift nr. 3.983.140, hvilke forbindelser isoleres fra mikroorganismer af slægten PeniciIlium.Hyperlipidemia, especially hypercholesterolemia, is known to be one of the major causes of cardiopathy, such as heart attack or arterial sclerosis. As a result, considerable research has been carried out to find compounds capable of reducing the amount of lipid, and especially the cholesterol 2Q sterol in the blood. A group of compounds of this type is disclosed in U.S. Patent No. 3,983,140, which compounds are isolated from microorganisms of the genus Penicillium.
Denne gruppe forbindelser betegnes kollektivt ML-236.This group of compounds is collectively referred to as ML-236.
25 ML-236A og NL-236B (to af forbindelserne i ML-236-komplekset, som er omhandlet i USA-patentskrift nr. 3.983.140) har henholdsvis formlen (II) og (III):25 ML-236A and NL-236B (two of the compounds of the ML-236 complex disclosed in U.S. Patent No. 3,983,140) have formulas (II) and (III), respectively:
so to'rV ΗΟγ Yso to'rV ΗΟγ Y
γ Yγ Y
x \x \
OH 1 9 TOH 1 9 T
CH, I I (ID CH I i (III)CH, I I (ID CH I i (III)
35 YyS Y yS35 YyS Y yS
XXX X XXXXX X XX
151273 2151273 2
Det har nu vist sig, at forbindelsen MB-530A kan fremstilles ved dyrkning af en stamme af arten Monascus ruber, og fremgangsmåden ifølge opfindelsen er i overensstemmelse hermed ejendommelig ved, at man dyrker en stamme af arten Monascus 5 ruber i et dyrkningsmedium derfor, og at den dannede MB-530A-forbindelse fraskilles fra dyrkningsmediet.It has now been found that the compound MB-530A can be prepared by growing a strain of the Monascus rubber species, and the method according to the invention is characterized by cultivating a strain of the Monascus 5 rubber species in a culture medium therefor, and that the MB-530A compound formed is separated from the culture medium.
MB-530A fremstilles fortrinsvis ved dyrkning af stammen Monascus ruber SANK 15177. Denne stamme blev deponeret den 27.MB-530A is preferably produced by cultivating the strain Monascus ruber SANK 15177. This strain was deposited on the 27th.
10 april 1979 under accessionsnummeret FERM 4956 hos The Fermentation Research Institute, Agency of Industrial Science and Technology, Ministry of International Trade and Industry,April 10, 1979 under the accession number FERM 4956 at The Fermentation Research Institute, Agency of Industrial Science and Technology, Ministry of International Trade and Industry,
Japan, og den 25. januar 1980 under accessionsnummeret NRRL 12081 hos The Agricultural Research Service Culture Collection, 15 Northern Regional Research Laboratory, Peoria, Illinois, U.S.A.Japan, and on January 25, 1980 under accession number NRRL 12081 at The Agricultural Research Service Culture Collection, 15 Northern Regional Research Laboratory, Peoria, Illinois, U.S.A.
Fra beskrivelsen til den danske patentansøgning nr 731/80, som svarer til fremlæggelsesskrift nr. 148.807, må det anses for kendt at fremstille monacolin K med formlen (IV): 20From the specification to Danish patent application No. 731/80, which corresponds to the present disclosure no. 148.807, it must be considered known to produce monacoline K of formula (IV): 20
HS VHS V
Y o 25 i i ^ 0 CH3\Yv>^k (IV) ^ Ύ' CH-30 3 ved dyrkning af stammer af arten Monacus ruber, bl.a. Monacus 35 ruber SANK 15.177.Y o 25 i i ^ 0 CH3 \ Yv> ^ k (IV) ^ Ύ 'CH-30 3 by cultivating strains of the species Monacus ruber, i.a. Monacus 35 ruber SANK 15.177.
151273 3151273 3
Fra beskrivelsen til den danske patentansøgning nr. 461/81 må det anses for kendt at fremstille bl.a. MB-530A ved en kemisk fremgangsmåde.From the description to the Danish patent application no. 461/81, it must be considered known to produce, inter alia, MB-530A by a chemical process.
5 Forbindelsen MB-530A kan fremstilles ved dyrkning af den udvalgte mikroorganisme i et dyrkningssubstrat under aerobe betingelser under anvendelse af den samme teknik, som er velkendt til dyrkning af svampe og andre mikroorganismer. For eksempel kan den valgte stamme af Monacus ruber først dyrkes IQ på et egnet medium, og den producerede mikroorganisme kan derefter opsamles og podes på og dyrkes på et andet dyrkningsmedium til fremstilling af den ønskede MB-530A-forbindelse.The compound MB-530A can be prepared by culturing the selected microorganism in a culture substrate under aerobic conditions using the same technique well known for growing fungi and other microorganisms. For example, the selected strain of Monacus rubber can first be grown IQ on a suitable medium and the microorganism produced can then be collected and seeded and grown on another culture medium to prepare the desired MB-530A compound.
Det til formeringen af mikroorganismen benyttede dyrkningsmedium og det til produktionen af MB-530A benyttede dyrknings-15 medium kan være ens eller forskellige.The culture medium used for the propagation of the microorganism and the culture medium used for the production of MB-530A may be the same or different.
Ethvert velkendt dyrkningsmedium til dyrkning af svampe kan benyttes, forudsat at det, som der er velkendt, indeholder de nødvendige næringsstoffer, især en assimilerbar carbonkil-20 de og en assimilerbar nitrogenkilde. Eksempler på sådanne kilder for assimilerbart carbon indbefatter glucose, maltose, dextrin, stivelse, lactose, sucrose og glycerol. Af disse kilder er glucose, glycerol og stivelse særlig foretrukne til fremstilling af MB-530A. Eksempler på egnede kilder for 25 assimilerbart nitrogen er pepton, kødekstrakt, gær, gærekstrakt, sojabønnemel, jordnøddemel, majsstøbevæske, risklid og uorganiske nitrogenkilder. Af disse nitrogenkilder er majsstøbevæske og pepton særlig foretrukne. Ved fremstilling af MB-530A kan et uorganisk salt og/eller et metalsalt om nødvendigt 30 sættes til dyrkningsmediet. Endvidere kan om nødvendigt en mindre mængde af et tungt metal også tilsættes.Any well-known culture medium for growing mushrooms can be used provided that, as is well known, it contains the necessary nutrients, in particular an assimilable carbon source and an assimilable nitrogen source. Examples of such sources of assimilable carbon include glucose, maltose, dextrin, starch, lactose, sucrose and glycerol. Of these sources, glucose, glycerol and starch are particularly preferred for the preparation of MB-530A. Examples of suitable sources for assimilable nitrogen are peptone, meat extract, yeast, yeast extract, soybean meal, peanut flour, corn mold liquid, rice bran and inorganic nitrogen sources. Of these nitrogen sources, corn molding liquid and peptone are particularly preferred. In preparing MB-530A, an inorganic salt and / or a metal salt can be added to the culture medium if necessary. Furthermore, if necessary, a smaller amount of a heavy metal can also be added.
Mikroorganismen dyrkes fortrinsvis under aerobe betingelser under anvendelse af dyrkningsmetoder, der er velkendte indenfor 35 teknikken, f.eks. fast dyrkning, rystedyrkning eller dyrkning under luftning og omrøring. Mikroorganismen vil vokse over et bredt temperaturinterval, f.eks. 7 til 40°C, men til 151273 4 fremstilling af MB-530A ligger den mere foretrukne dyrkningstemperatur indenfor intervallet fra 20 til 30°C.The microorganism is preferably grown under aerobic conditions using cultivation methods well known in the art, e.g. solid culture, shaking or aeration and stirring. The microorganism will grow over a wide range of temperatures, e.g. 7 to 40 ° C, but for the preparation of MB-530A, the more preferred culture temperature is within the range of 20 to 30 ° C.
Under dyrkningen af mikroorganismen kan produktionen af MB-530A 5 måles ved prøveudtagning af dyrkningsmedium og måling af mediets fysiologiske aktivitet ved hjælp af velkendte forsøg. Dyrkningen kan derefter fortsættes, indtil en væsentlig akkumulering af MB-530A er blevet opnået i dyrkningsmediet, på hvilket tidspunkt MB-530A-forbindelsen derefter kan isoleres ^0 og udvindes fra dyrkningsmediet ved hjælp af enhver egnet kombination af isolationsteknik, der vælges under hensyntagen til dets fysiske og kemiske egenskaber. For eksempel kan enhver af eller alle de nedenfor anførte isolationsmetoder anvendes: ^5 Ekstraktion af væsken fra dyrkningssubstratet med et hydrofilt opløsningsmiddel (såsom diethylether, ethylacetat, chloroform eller benzen), koncentrering, f.eks. ved afdampning af noget eller en del af opløsningsmidlet under formindsket tryk, opløsning i et mere polært opløsningsmiddel (såsom acetone 2q eller en alkohol), fjernelse af urenheder med et mindre polært opløsningsmiddel (såsom petroleumsether eller hexan), gelfiltrering gennem en søjle af et materiale, såsom "Sephadex" (et handelsnavn for et materiale, der fås fra Pharmacia Co. Limited, U.S.A.), absorptionskromatografi med aktivt carbon 25 eller silicagel og andre lignende metoder. Ved anvendelse .During the cultivation of the microorganism, the production of MB-530A 5 can be measured by sampling culture medium and measuring the physiological activity of the medium by well known experiments. Cultivation can then be continued until a significant accumulation of MB-530A has been obtained in the culture medium, at which time the MB-530A compound can then be isolated and recovered from the culture medium by any suitable combination of isolation technique selected taking into account its physical and chemical properties. For example, any or all of the isolation methods listed below may be used: Extraction of the liquid from the culture substrate with a hydrophilic solvent (such as diethyl ether, ethyl acetate, chloroform or benzene), concentration, e.g. by evaporation of some or all of the solvent under reduced pressure, dissolving in a more polar solvent (such as acetone 2q or an alcohol), removing impurities with a less polar solvent (such as petroleum ether or hexane), gel filtration through a column of a material , such as "Sephadex" (a trade name for a material obtained from Pharmacia Co. Limited, USA), activated carbon 25 or silica gel absorption chromatography, and other similar methods. When used.
af en passende kombination af disse metoder kan den ønskede MB-530A-forbindelse isoleres fra dyrkningssubstratet som et rent stof. 1 2 3 4 5 6by a suitable combination of these methods, the desired MB-530A compound can be isolated from the culture substrate as a pure substance. 1 2 3 4 5 6
Den ifølge opfindelsen fremstillede forbindelse har vist sig 2 at have en specifik inhiberende virkning over for 3-hydroxy-3- 3 methylglutarylcoenzym A reduktase (HMG-CoA reduktase), som 4 er det hastigheds-kontrollerende enzym ved biosyntesen af 5 cholesterol.The compound of the invention has been found to have a specific inhibitory effect against 3-hydroxy-3- 3 methylglutaryl coenzyme A reductase (HMG-CoA reductase), which 4 is the rate-controlling enzyme in the biosynthesis of 5 cholesterol.
66
Fremstillingen af forbindelsen MB-530A illustreres yderligere i det efterfølgende eksempel.The preparation of compound MB-530A is further illustrated in the following example.
151273 5151273 5
EksempelExample
Fremstilling af MB-530APreparation of MB-530A
5 300 1 af et dyrkningsmedium med en pH-værdi på 5,5 før steri lisering og indeholdende 5% vægt/volumen glucose, 0,5% vægt/ volumen maj sstøbevæske og 2% vægt/volumen pepton (Kyokuto fabrikat, fås fra Kyokuto Seiyaku KK, Japan) og 0,5% ammonium-chlorid blev fyldt på en 600 1 gæringsbeholder og podet med 10 en kultur af Monascus ruber SANK 15177 (FERM 4956, NRRL 12081).5,300 l of a culture medium with a pH of 5.5 before sterilization containing 5% w / v glucose, 0.5% w / v maize casting liquid and 2% w / v peptone (Kyokuto make, available from Kyokuto Seiyaku KK, Japan) and 0.5% ammonium chloride were charged to a 600 l fermentation vessel and seeded with a culture of Monascus ruber SANK 15177 (FERM 4956, NRRL 12081).
Dyrkning af microorganismen blev fortsat i 120 timer ved 27°C med en beluftningshastighed på 300 1/min og omrøring med 190 omdrejninger pr. minut.Culture of the microorganism was continued for 120 hours at 27 ° C with an aeration rate of 300 l / min and stirring at 190 rpm. minute.
15 Ved afslutningen af dette tidsrum blev dyrkningssubstratet filtreret i en filterpresse til opnåelse af et filtrat og en filterkage omfattende våde celler af microorganismen.At the end of this time, the culture substrate was filtered into a filter press to obtain a filtrate and a filter cake comprising wet cells of the microorganism.
Filtratet blev indstillet til en pH-værdi på 3,0 ved tilsæt-20 ning af 6N saltsyre og derpå ekstraheret med 400 1 ethylacetat.The filtrate was adjusted to a pH of 3.0 by the addition of 6N hydrochloric acid and then extracted with 400 L of ethyl acetate.
Ekstrakten (ca. 400 1) blev koncentreret ved inddampning under formindsket tryk og derefter afvandet over vandfrit natriumsulfat, hvorefter den blev inddampet til tørhed til opnåelse af ca. 60 g af et olieagtigt produkt. Dette olieagtige pro-25 dukt blev vasket med ethylcyklohexan og med hexan, og resten (20 g), blev separeret ved hjælp af kromatografi under anvendelse af et væskekromatografiapparat til udtagning af prøver med stort volumen (System 500 væskekromatografi, fremstillet afThe extract (about 400 L) was concentrated by evaporation under reduced pressure and then dewatered over anhydrous sodium sulfate, then evaporated to dryness to give ca. 60 g of an oily product. This oily product was washed with ethyl cyclohexane and with hexane, and the residue (20 g) was separated by chromatography using a high volume liquid chromatography apparatus (System 500 liquid chromatography, prepared by
Waters Co., USA), idet der blev elueret . med 60% volumen/vol-30 urnen vandig methanol.Fraktioner med en kromatografisk retentionstid på 6 minutter blev opsamlet og koncentreret ved inddampning under formindsket tryk til opnåelse af 100 mg af den ønskede MB-530A-forbindelse som et olieagtigt produkt. Denne olieagtige MB-530A-forbindelse blev rekrystalliseret fra en blanding af acetone og diethylether til opnåelse af 57 mg af det ønskede produkt i form af farveløse nåle med følgende egenskaber :Waters Co., USA), eluting. with 60% v / v aqueous methanol. Fractions with chromatographic retention time of 6 minutes were collected and concentrated by evaporation under reduced pressure to give 100 mg of the desired MB-530A compound as an oily product. This oily MB-530A compound was recrystallized from a mixture of acetone and diethyl ether to give 57 mg of the desired product in the form of colorless needles having the following properties:
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK542085A DK159439C (en) | 1980-03-31 | 1985-11-22 | ANALOGY PROCEDURE FOR PREPARING CHOLESTEROL SYNTHESIS INHIBITORS |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP55041292A JPH0692381B2 (en) | 1980-03-31 | 1980-03-31 | MB-530A derivative |
JP4129280 | 1980-03-31 |
Publications (3)
Publication Number | Publication Date |
---|---|
DK145481A DK145481A (en) | 1981-10-01 |
DK151273B true DK151273B (en) | 1987-11-16 |
DK151273C DK151273C (en) | 1988-07-04 |
Family
ID=12604367
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK145481A DK151273C (en) | 1980-03-31 | 1981-03-31 | PROCEDURE FOR THE PREPARATION OF THE CHOLESTEROL BIOSYNTHESE INHIBITOR MB-530A. |
DK032290A DK32290A (en) | 1980-03-31 | 1990-02-07 | APPLICATION OF 8'-ACYLED DERIVATIVES OF THE INTERMEDIATE COMPOUND MB-530A FOR THE PREPARATION OF A MEDICINE FOR TREATING HYPERCHOLESTEROLAEMIA |
DK032190A DK167805B1 (en) | 1980-03-31 | 1990-02-07 | INTERMEDIATE FOR THE PREPARATION OF CHOLESTEROL SYNTHESIS INHIBITORS |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK032290A DK32290A (en) | 1980-03-31 | 1990-02-07 | APPLICATION OF 8'-ACYLED DERIVATIVES OF THE INTERMEDIATE COMPOUND MB-530A FOR THE PREPARATION OF A MEDICINE FOR TREATING HYPERCHOLESTEROLAEMIA |
DK032190A DK167805B1 (en) | 1980-03-31 | 1990-02-07 | INTERMEDIATE FOR THE PREPARATION OF CHOLESTEROL SYNTHESIS INHIBITORS |
Country Status (15)
Country | Link |
---|---|
JP (1) | JPH0692381B2 (en) |
AT (1) | ATA150781A (en) |
AU (1) | AU6893281A (en) |
BE (1) | BE888214A (en) |
CH (1) | CH646966A5 (en) |
DE (2) | DE3112566A1 (en) |
DK (3) | DK151273C (en) |
FI (1) | FI810991L (en) |
FR (1) | FR2479222A1 (en) |
GB (1) | GB2073193A (en) |
IE (1) | IE52367B1 (en) |
IT (1) | IT1144325B (en) |
MX (1) | MX9203567A (en) |
NL (1) | NL8101592A (en) |
SE (1) | SE461590B (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4472426A (en) * | 1982-12-22 | 1984-09-18 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
DE3682557D1 (en) * | 1985-09-13 | 1992-01-02 | Sankyo Co | HYDROXY-ML-236B DERIVATIVES, THEIR PRODUCTION AND USE. |
US4997848A (en) * | 1987-10-27 | 1991-03-05 | Sankyo Company, Limited | Octahydronaphthalene oxime derivatives for cholesterol synthesis inhibition |
US5075327A (en) * | 1988-08-10 | 1991-12-24 | Hoffmann-La Roche Inc. | Antipsoriatic agents |
US5073568A (en) * | 1988-11-14 | 1991-12-17 | Hoffmann-La Roche Inc. | Antipsoriatic agents |
US5021451A (en) * | 1988-11-14 | 1991-06-04 | Hoffman-La Roche Inc. | Method for inhibiting hyperproliferative diseases |
US5200549A (en) * | 1988-11-14 | 1993-04-06 | Hoffman-La Roche Inc. | Antipsoriatic agents |
US5159104A (en) * | 1991-05-01 | 1992-10-27 | Merck & Co., Inc. | Process to simvastatin ester |
FR2937537A1 (en) | 2008-10-29 | 2010-04-30 | Centre Nat Rech Scient | NANOPARTICLES OF STATIN |
KR101820099B1 (en) | 2013-01-18 | 2018-01-18 | 에스프린팅솔루션 주식회사 | resistive heat generating material, heating member and fusing device adopting the same |
US11970482B2 (en) | 2018-01-09 | 2024-04-30 | Ligand Pharmaceuticals Inc. | Acetal compounds and therapeutic uses thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK46181A (en) * | 1980-02-04 | 1981-08-05 | Merck & Co Inc | PROCEDURE FOR PRODUCING PYRANONES AND INTERMEDIATES FOR USE IN EXERCISING THE PROCEDURE |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5612114B2 (en) * | 1974-06-07 | 1981-03-18 | ||
JPS5925599B2 (en) * | 1979-02-20 | 1984-06-19 | 三共株式会社 | New physiologically active substance monacolin K and its production method |
US4231938A (en) * | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
GR69216B (en) * | 1979-06-15 | 1982-05-07 | Merck & Co Inc | |
ZA81703B (en) * | 1980-02-04 | 1982-09-29 | Merck & Co Inc | New antihypercholesterolemic compounds,intermediates and processes |
PT72394B (en) * | 1980-02-04 | 1982-09-06 | Merck & Co Inc | Process for preparing dihydro and tetrahydromevinoline hypocholesterolimics |
US4282155A (en) * | 1980-02-04 | 1981-08-04 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
-
1980
- 1980-03-31 JP JP55041292A patent/JPH0692381B2/en not_active Expired - Lifetime
-
1981
- 1981-03-27 IE IE698/81A patent/IE52367B1/en not_active IP Right Cessation
- 1981-03-30 DE DE19813112566 patent/DE3112566A1/en active Granted
- 1981-03-30 IT IT67438/81A patent/IT1144325B/en active
- 1981-03-30 CH CH215381A patent/CH646966A5/en not_active IP Right Cessation
- 1981-03-30 DE DE3153666A patent/DE3153666C2/en not_active Expired - Lifetime
- 1981-03-31 AT AT0150781A patent/ATA150781A/en not_active IP Right Cessation
- 1981-03-31 AU AU68932/81A patent/AU6893281A/en not_active Abandoned
- 1981-03-31 SE SE8102047A patent/SE461590B/en not_active Application Discontinuation
- 1981-03-31 NL NL8101592A patent/NL8101592A/en not_active Application Discontinuation
- 1981-03-31 FI FI810991A patent/FI810991L/en not_active Application Discontinuation
- 1981-03-31 GB GB8110075A patent/GB2073193A/en not_active Withdrawn
- 1981-03-31 BE BE0/204328A patent/BE888214A/en not_active IP Right Cessation
- 1981-03-31 FR FR8106403A patent/FR2479222A1/en active Granted
- 1981-03-31 DK DK145481A patent/DK151273C/en not_active IP Right Cessation
-
1990
- 1990-02-07 DK DK032290A patent/DK32290A/en not_active Application Discontinuation
- 1990-02-07 DK DK032190A patent/DK167805B1/en not_active IP Right Cessation
-
1992
- 1992-06-26 MX MX9203567A patent/MX9203567A/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK46181A (en) * | 1980-02-04 | 1981-08-05 | Merck & Co Inc | PROCEDURE FOR PRODUCING PYRANONES AND INTERMEDIATES FOR USE IN EXERCISING THE PROCEDURE |
Also Published As
Publication number | Publication date |
---|---|
DK32290D0 (en) | 1990-02-07 |
DE3112566A1 (en) | 1982-03-11 |
DK145481A (en) | 1981-10-01 |
IE810698L (en) | 1981-09-30 |
CH646966A5 (en) | 1984-12-28 |
IT1144325B (en) | 1986-10-29 |
NL8101592A (en) | 1981-10-16 |
FR2479222A1 (en) | 1981-10-02 |
AU6893281A (en) | 1981-10-08 |
IE52367B1 (en) | 1987-09-30 |
SE8102047L (en) | 1981-10-01 |
FI810991L (en) | 1981-10-01 |
SE461590B (en) | 1990-03-05 |
DE3112566C2 (en) | 1990-04-05 |
GB2073193A (en) | 1981-10-14 |
FR2479222B1 (en) | 1983-08-26 |
JPH0692381B2 (en) | 1994-11-16 |
BE888214A (en) | 1981-09-30 |
JPS56138181A (en) | 1981-10-28 |
DK167805B1 (en) | 1993-12-20 |
DK32190D0 (en) | 1990-02-07 |
IT8167438A0 (en) | 1981-03-30 |
MX9203567A (en) | 1992-09-01 |
DK151273C (en) | 1988-07-04 |
DE3153666C2 (en) | 1993-11-11 |
DK32190A (en) | 1990-02-07 |
DK32290A (en) | 1990-02-07 |
ATA150781A (en) | 1983-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK149095B (en) | PROCEDURE FOR PREPARING A CHOLESTEROL SYNTHESIS INHIBITIVE COMPOUND called MONACOLIN K | |
BG62852B1 (en) | Method for lovastatin isolation | |
DK151273B (en) | PROCEDURE FOR THE PREPARATION OF THE CHOLESTEROL BIOSYNTHESE INHIBITOR MB-530A. | |
CN102965290A (en) | Pichia kudriavzevii ZJPH0802 and application thereof in preparation of curcumin derivatives | |
NZ250344A (en) | Zearalenone analogues, their preparation from a fungal fermentation, the fungal strain, and pharmaceutical compositions | |
JP3854866B2 (en) | Method for producing mycophenolic acid and derivatives thereof | |
EP0356291B1 (en) | Process for the microbiological production of gamma-decalactone (R) and gamma-octalactone (R) | |
EP0043280B1 (en) | Process for preparing a macrolide | |
CN102329829B (en) | Method for converting daidzein into 8-hydroxydaidzein by utilizing penicillium | |
CN106957881B (en) | Preparation method of curcumin derivative | |
JPH0246294A (en) | Production of angnocyclinone from streptomyces microorganism and production thereof | |
US3564019A (en) | Tetracyclic lactone antifungal agents | |
JP2966859B2 (en) | Novel bioactive substance dioctatin and method for producing the same | |
JPH0625277A (en) | Bacterium producing novel testosterone-5alpha-reductase-inhibiting substance, sna-4606, novel testosterone-5-reductase-inhibiting substance, sna-4606 and its production | |
JPH05170769A (en) | New compound q-11270 or its production | |
JP3641013B2 (en) | Novel cell adhesion inhibitors Macrospheride A and B and process for producing them | |
EP0337548A2 (en) | HMG-COA reductase inhibitors produced by nocardia SP. (MA6455)(ATCC 53695) | |
JPH07242636A (en) | Fo-3216 substance and its production | |
EP1080220A1 (en) | New biotechnological process for preparing hydroxylated ml-236b derivatives, known as m-4 and m-4', and analogues thereof | |
JPS5945360B2 (en) | Production method of physiologically active substance ML-236B | |
JPS5840475B2 (en) | New physiologically active substance ML-236A and its manufacturing method | |
EP0629184A1 (en) | TETRALIN DERIVATIVES AS HMG-CoA REDUCTASE INHIBITORS | |
US3634461A (en) | Spirostan derivative | |
JPS6219159B2 (en) | ||
DK165990B (en) | Hypocholesterolaemic agent monacolin K - produced by culturing Monascus strain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PTS | Application withdrawn | ||
PUP | Patent expired |